维甲酸受体RARα与RXRα在卵巢癌中的表达和预后研究
维甲酸受体RARα与RXRα在卵巢癌中的表达和预后研究
刘冲,  徐金峰,  安晓静,  石群立,  刘琦,  周航波,  马恒辉
南京大学医学院临床学院/南京军区南京总医院病理科

 

目的 探讨维甲酸受体RARα与RXRα在卵巢癌中的表达及其与临床病理参数和预后的相关性及意义。方法 应用免疫组织化学方法测定93例原发性卵巢癌组织标本中RARα与RXRα的表达,采用pearson χ2检验分别分析RARα与RXRα表达与临床病理参数的意义,运用非参数spearman相关系数检验两者之间的相关性,并对随访结果进行Cox生存分析。结果 93例卵巢癌组织中RARα、RXRα阳性表达率分别为68.8%、52.7%。RARα表达与卵巢癌患者年龄、肿瘤大小及转移(包括淋巴结)无关(P>0.05),而与病理分级、组织学类型及FIGO分期有关(p<0.05)。RXRα表达与卵巢癌患者年龄、肿瘤大小、组织学类型、FIGO分期及转移无关(P>0.05),而与病理分级有关(p<0.05)。经spearman相关系数检验RARα与RXRα在卵巢癌中的表达呈正相关(r=0.4432,P=0.000),二者协同表达。Cox单因素分析和多因素分析,结果均显示卵巢癌患者的预后与FIGO分期和RARα表达有关,二者是影响卵巢癌预后的因素(p<0.05),而患者的年龄、肿瘤大小、组织学类型、病理分级与预后无关(P>0.05)。结论 RARα、RXRα二者高表达提示肿瘤恶性程度高,FIGO分期和RARα表达与卵巢癌患者的预后关系密切, 检测RARα表达可作为临床诊断和评估卵巢癌患者预后有效的生物学指标之一。维甲酸受体在调控肿瘤发生、诱导分化上有重要的作用,可以被用来作为卵巢癌治疗的一个靶点。
The research of of retinoic acid receptorRARα&RXRαin Ovarian Carcinoma:expression and prognosis
Liu Chong,Xu Jinfeng,An Xiaojing,Shi Qunli,Liu Qi,Zhou Hangbo,Ma Henghui
Department of Pathology, Nanjing University Medical College/Nanjing General Hospital of Nanjing Command, Nanjing, Jiangsu, 210002, China.
 
Abstract:
Objective To investigate the retinoic acid receptor RARα and RXRα expression in ovarian cancer and its relationship with clinicopathological parameters and prognosis.Method 93 cases of primarily ovarian cancer tissue samples was determined by immunohistochemistry and analyze significance of expression both RARα and RXRα. Discuss the significance of expression of RXRα and RARα with clinical of pathological parameters by pearson χ2 test .Use non-parametric spearman correlation coefficient between the two relevance.The follow-up results was studied by Cox survival analysis. Results  In the 93 cases of ovarian cancer,the expression rates of RARα and RXRα were 68.8%, 52.7%. There were no significant of RARα expression with patient age, tumor size and metastasis (including lymph nodes) (P> 0.05), but with ovarian cancer tumor grade, histologic type and FIGO stage (p<0.05). There were no significant of RXRα expression with patient age, tumor size, histological type, FIGO stage and metastasis (P> 0.05), but with the pathological grading ovarian cancer (p <0.05). The spearman correlation coefficient test was showed that RARα and RXRα expression in ovarian cancer was positively correlated (r = 0.4432, P = 0.000), both coordinated expression. In the whole cases with followed-up data ,Cox univariate analysis and multivariate analysis showed that FIGO stage and RARα expression were related to prognosis of patients with ovarian cancer, both are the factors affecting the prognosis of ovarian cancer (p <0.05). There were no relationship with age, tumor size, histological type, histological grade to prognosis (P> 0.05).Conclusion High expression of RARα and RXRα were suggested highly malignant tumor. FIGO stage, RARα were closed to the prognosis of patients with ovarian cancer, especially test RARα expression may be an useful and effective biological indicator as diagnostic testing and assessment of prognosis of ovarian cancer patients.Retinoic acid receptor has an important role in the regulation of tumorigenesis, induction of differentiation, can be used as a target for ovarian cancer therapy.

  2010年中华医学会病理学分会学术年会·秘书处
  中华医学会 学术会务部
  地址:北京市东城区东四西大街42号423室 / 邮编:100710  
  电话:010-8515 8473 / 传真:010-6512 3754
  邮箱:
leighdai@cma.org.cn / 网址:www.cmacps.org